Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Identifieur interne : 001950 ( Main/Exploration ); précédent : 001949; suivant : 001951Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Auteurs : Charlotte Fribbens [États-Unis] ; Ben O'Leary [États-Unis] ; Lucy Kilburn [États-Unis] ; Sarah Hrebien [États-Unis] ; Isaac Garcia-Murillas [États-Unis] ; Matthew Beaney [États-Unis] ; Massimo Cristofanilli [États-Unis] ; Fabrice Andre [États-Unis] ; Sherene Loi [États-Unis] ; Sibylle Loibl [États-Unis] ; John Jiang [États-Unis] ; Cynthia Huang Bartlett [États-Unis] ; Maria Koehler [États-Unis] ; Mitch Dowsett [États-Unis] ; Judith M. Bliss [États-Unis] ; Stephen R D. Johnston [États-Unis] ; Nicholas C. Turner [États-Unis]Source :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology [ 1527-7755 ] ; 2016.
Descripteurs français
- KwdFr :
- ADN tumoral (génétique), ADN tumoral (sang), Adulte d'âge moyen, Androstadiènes (usage thérapeutique), Femelle, Humains, Nitriles (administration et posologie), Oestradiol (administration et posologie), Oestradiol (analogues et dérivés), Oestradiol (usage thérapeutique), Pipérazines (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Pyridines (administration et posologie), Récepteur alpha des oestrogènes (génétique), Récepteur alpha des oestrogènes (sang), Sujet âgé, Survie sans rechute, Triazoles (administration et posologie), Tumeurs du sein (génétique), Tumeurs du sein (sang), Tumeurs du sein (traitement médicamenteux), Études prospectives, Études rétrospectives.
- MESH :
- administration et posologie : Nitriles, Oestradiol, Pipérazines, Pyridines, Triazoles.
- analogues et dérivés : Oestradiol.
- génétique : ADN tumoral, Récepteur alpha des oestrogènes, Tumeurs du sein.
- sang : ADN tumoral, Récepteur alpha des oestrogènes, Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Androstadiènes, Oestradiol, Protocoles de polychimiothérapie antinéoplasique.
- Adulte d'âge moyen, Femelle, Humains, Sujet âgé, Survie sans rechute, Études prospectives, Études rétrospectives.
English descriptors
- KwdEn :
- Aged, Androstadienes (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Breast Neoplasms (blood), Breast Neoplasms (drug therapy), Breast Neoplasms (genetics), DNA, Neoplasm (blood), DNA, Neoplasm (genetics), Disease-Free Survival, Estradiol (administration & dosage), Estradiol (analogs & derivatives), Estradiol (therapeutic use), Estrogen Receptor alpha (blood), Estrogen Receptor alpha (genetics), Female, Humans, Middle Aged, Nitriles (administration & dosage), Piperazines (administration & dosage), Prospective Studies, Pyridines (administration & dosage), Retrospective Studies, Triazoles (administration & dosage).
- MESH :
- chemical , administration & dosage : Estradiol, Nitriles, Piperazines, Pyridines, Triazoles.
- chemical , analogs & derivatives : Estradiol.
- chemical , blood : DNA, Neoplasm, Estrogen Receptor alpha.
- chemical , genetics : DNA, Neoplasm, Estrogen Receptor alpha.
- chemical , therapeutic use : Androstadienes, Estradiol.
- blood : Breast Neoplasms.
- drug therapy : Breast Neoplasms.
- genetics : Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Disease-Free Survival, Female, Humans, Middle Aged, Prospective Studies, Retrospective Studies.
Abstract
ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that represent the development of the current standard therapy for estrogen receptor-positive advanced breast cancer.
DOI: 10.1200/JCO.2016.67.3061
PubMed: 27269946
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001985
- to stream PubMed, to step Curation: 001961
- to stream PubMed, to step Checkpoint: 001961
- to stream Ncbi, to step Merge: 003657
- to stream Ncbi, to step Curation: 003657
- to stream Ncbi, to step Checkpoint: 003657
- to stream Main, to step Merge: 001945
- to stream Main, to step Curation: 001950
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.</title><author><name sortKey="Fribbens, Charlotte" sort="Fribbens, Charlotte" uniqKey="Fribbens C" first="Charlotte" last="Fribbens">Charlotte Fribbens</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="O Leary, Ben" sort="O Leary, Ben" uniqKey="O Leary B" first="Ben" last="O'Leary">Ben O'Leary</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Kilburn, Lucy" sort="Kilburn, Lucy" uniqKey="Kilburn L" first="Lucy" last="Kilburn">Lucy Kilburn</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Hrebien, Sarah" sort="Hrebien, Sarah" uniqKey="Hrebien S" first="Sarah" last="Hrebien">Sarah Hrebien</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Garcia Murillas, Isaac" sort="Garcia Murillas, Isaac" uniqKey="Garcia Murillas I" first="Isaac" last="Garcia-Murillas">Isaac Garcia-Murillas</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Beaney, Matthew" sort="Beaney, Matthew" uniqKey="Beaney M" first="Matthew" last="Beaney">Matthew Beaney</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="Andre">Fabrice Andre</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Jiang, John" sort="Jiang, John" uniqKey="Jiang J" first="John" last="Jiang">John Jiang</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Bartlett, Cynthia Huang" sort="Bartlett, Cynthia Huang" uniqKey="Bartlett C" first="Cynthia Huang" last="Bartlett">Cynthia Huang Bartlett</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Bliss, Judith M" sort="Bliss, Judith M" uniqKey="Bliss J" first="Judith M" last="Bliss">Judith M. Bliss</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Johnston, Stephen R D" sort="Johnston, Stephen R D" uniqKey="Johnston S" first="Stephen R D" last="Johnston">Stephen R D. Johnston</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY. nicholas.turner@icr.ac.uk.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27269946</idno><idno type="pmid">27269946</idno><idno type="doi">10.1200/JCO.2016.67.3061</idno><idno type="wicri:Area/PubMed/Corpus">001985</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001985</idno><idno type="wicri:Area/PubMed/Curation">001961</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001961</idno><idno type="wicri:Area/PubMed/Checkpoint">001961</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001961</idno><idno type="wicri:Area/Ncbi/Merge">003657</idno><idno type="wicri:Area/Ncbi/Curation">003657</idno><idno type="wicri:Area/Ncbi/Checkpoint">003657</idno><idno type="wicri:Area/Main/Merge">001945</idno><idno type="wicri:Area/Main/Curation">001950</idno><idno type="wicri:Area/Main/Exploration">001950</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.</title><author><name sortKey="Fribbens, Charlotte" sort="Fribbens, Charlotte" uniqKey="Fribbens C" first="Charlotte" last="Fribbens">Charlotte Fribbens</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="O Leary, Ben" sort="O Leary, Ben" uniqKey="O Leary B" first="Ben" last="O'Leary">Ben O'Leary</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Kilburn, Lucy" sort="Kilburn, Lucy" uniqKey="Kilburn L" first="Lucy" last="Kilburn">Lucy Kilburn</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Hrebien, Sarah" sort="Hrebien, Sarah" uniqKey="Hrebien S" first="Sarah" last="Hrebien">Sarah Hrebien</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Garcia Murillas, Isaac" sort="Garcia Murillas, Isaac" uniqKey="Garcia Murillas I" first="Isaac" last="Garcia-Murillas">Isaac Garcia-Murillas</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Beaney, Matthew" sort="Beaney, Matthew" uniqKey="Beaney M" first="Matthew" last="Beaney">Matthew Beaney</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="Andre">Fabrice Andre</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Jiang, John" sort="Jiang, John" uniqKey="Jiang J" first="John" last="Jiang">John Jiang</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Bartlett, Cynthia Huang" sort="Bartlett, Cynthia Huang" uniqKey="Bartlett C" first="Cynthia Huang" last="Bartlett">Cynthia Huang Bartlett</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Bliss, Judith M" sort="Bliss, Judith M" uniqKey="Bliss J" first="Judith M" last="Bliss">Judith M. Bliss</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Johnston, Stephen R D" sort="Johnston, Stephen R D" uniqKey="Johnston S" first="Stephen R D" last="Johnston">Stephen R D. Johnston</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author><author><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name><affiliation wicri:level="2"><nlm:affiliation>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY. nicholas.turner@icr.ac.uk.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title><idno type="eISSN">1527-7755</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Androstadienes (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Breast Neoplasms (blood)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (genetics)</term><term>DNA, Neoplasm (blood)</term><term>DNA, Neoplasm (genetics)</term><term>Disease-Free Survival</term><term>Estradiol (administration & dosage)</term><term>Estradiol (analogs & derivatives)</term><term>Estradiol (therapeutic use)</term><term>Estrogen Receptor alpha (blood)</term><term>Estrogen Receptor alpha (genetics)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Nitriles (administration & dosage)</term><term>Piperazines (administration & dosage)</term><term>Prospective Studies</term><term>Pyridines (administration & dosage)</term><term>Retrospective Studies</term><term>Triazoles (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN tumoral (génétique)</term><term>ADN tumoral (sang)</term><term>Adulte d'âge moyen</term><term>Androstadiènes (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Nitriles (administration et posologie)</term><term>Oestradiol (administration et posologie)</term><term>Oestradiol (analogues et dérivés)</term><term>Oestradiol (usage thérapeutique)</term><term>Pipérazines (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Pyridines (administration et posologie)</term><term>Récepteur alpha des oestrogènes (génétique)</term><term>Récepteur alpha des oestrogènes (sang)</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Triazoles (administration et posologie)</term><term>Tumeurs du sein (génétique)</term><term>Tumeurs du sein (sang)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Études prospectives</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Estradiol</term><term>Nitriles</term><term>Piperazines</term><term>Pyridines</term><term>Triazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Estradiol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>DNA, Neoplasm</term><term>Estrogen Receptor alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA, Neoplasm</term><term>Estrogen Receptor alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Androstadienes</term><term>Estradiol</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Nitriles</term><term>Oestradiol</term><term>Pipérazines</term><term>Pyridines</term><term>Triazoles</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Oestradiol</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ADN tumoral</term><term>Récepteur alpha des oestrogènes</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>ADN tumoral</term><term>Récepteur alpha des oestrogènes</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Androstadiènes</term><term>Oestradiol</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Prospective Studies</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Études prospectives</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that represent the development of the current standard therapy for estrogen receptor-positive advanced breast cancer.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Fribbens, Charlotte" sort="Fribbens, Charlotte" uniqKey="Fribbens C" first="Charlotte" last="Fribbens">Charlotte Fribbens</name></region><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="Andre">Fabrice Andre</name><name sortKey="Bartlett, Cynthia Huang" sort="Bartlett, Cynthia Huang" uniqKey="Bartlett C" first="Cynthia Huang" last="Bartlett">Cynthia Huang Bartlett</name><name sortKey="Beaney, Matthew" sort="Beaney, Matthew" uniqKey="Beaney M" first="Matthew" last="Beaney">Matthew Beaney</name><name sortKey="Bliss, Judith M" sort="Bliss, Judith M" uniqKey="Bliss J" first="Judith M" last="Bliss">Judith M. Bliss</name><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name><name sortKey="Garcia Murillas, Isaac" sort="Garcia Murillas, Isaac" uniqKey="Garcia Murillas I" first="Isaac" last="Garcia-Murillas">Isaac Garcia-Murillas</name><name sortKey="Hrebien, Sarah" sort="Hrebien, Sarah" uniqKey="Hrebien S" first="Sarah" last="Hrebien">Sarah Hrebien</name><name sortKey="Jiang, John" sort="Jiang, John" uniqKey="Jiang J" first="John" last="Jiang">John Jiang</name><name sortKey="Johnston, Stephen R D" sort="Johnston, Stephen R D" uniqKey="Johnston S" first="Stephen R D" last="Johnston">Stephen R D. Johnston</name><name sortKey="Kilburn, Lucy" sort="Kilburn, Lucy" uniqKey="Kilburn L" first="Lucy" last="Kilburn">Lucy Kilburn</name><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name><name sortKey="O Leary, Ben" sort="O Leary, Ben" uniqKey="O Leary B" first="Ben" last="O'Leary">Ben O'Leary</name><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001950 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001950 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27269946
|texte= Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27269946" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |